Therefore, selective inhibition of CD90+ and CXCR4+ cells, resulting in reduced cancer metastasis, may provide significant improvements in the current therapeutic approaches in HCC patients (Zhu et al., 2015). This evidence concerns the gene CXCR4 and cancer.